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Objective: Although the surgical management of brachiocephalic disease is well established, evolving endovascular
techniques present new options for treatment. We explored the potential benefits and drawbacks of these interventions in
terms of outcome.
Methods: From 1966 to 2004, 391 consecutive patients (43.7% male; mean age, 61.9 years) with single-vessel brachioce-
phalic disease were treated with either operative bypass (group A; n 229) or percutaneous transluminal angioplasty and
stenting (group B; n  162).
Results: All patients were asymptomatic after surgery or endovascular intervention. Group A and group B had similar
operative mortality (0.9% vs 0.6%) and stroke (1.3% vs 0%) rates. However, 5 years after the procedure, group A had
significantly better freedom from graft or intervention failure (92.7% 2.1%) than did group B (83.9% 3.7%; P .03,
Kaplan-Meier analysis; P  .001, Cox regression analysis). At 10 years, group A had the following rates of actuarial
freedom from specific events: death, 73.7%  4.6%; myocardial infarction, 84.2%  3.6%; stroke, 91.4%  3.4%; graft
failure, 88.1%  3.3%; coronary revascularization, 69.8%  5.1%; and other vascular operation, 70.7%  4.6%.
Endovascular intervention involved less initial cost (mean savings, $8787 per procedure), was less invasive, and did not
necessitate general anesthesia. On satisfaction questionnaires, 96.5% of patients receiving an endovascular intervention
and 95.1% of patients receiving operative bypass for single-vessel brachiocephalic disease subjectively rated their
treatment as “good” or “very good.”
Conclusions:Operative bypass and endovascular intervention for single-vessel brachiocephalic disease are both associated
with acceptably low operative morbidity and mortality. Operative bypass produces significantly better mid-term freedom
from graft or intervention failure than endovascular intervention and produces excellent long-term freedom from failure.
Endovascular intervention offers tangible benefits regarding cost, level of invasiveness, and subjective patient satisfaction.
Undetermined are the differences between the procedures regarding long-term durability, patterns of failure, efficacy as
an adjunct to coronary artery bypass grafting, need for anticoagulation, efficacy as treatment for complex (multivessel)
disease, and long-term cost. ( J Vasc Surg 2005;42:55-61.)In contrast to extrathoracic bypass for either innomi-
nate artery or multivessel brachiocephalic (BC) disease,
extrathoracic bypass for single-vessel subclavian artery
(SCA) or common carotid artery (CCA) BC disease has
produced excellent long-term durability with acceptably
low operative mortality and morbidity.1-3 Although the
surgical management of single-vessel BC disease is well
established, the introduction of endovascular techniques
has permitted new pathways for the treatment of BC dis-
ease. We explore the potential benefits and drawbacks of
these interventions in terms of outcome.
METHODS
We reviewed the records of 391 consecutive patients
(mean age, 61.9 years; 43.7% male) treated at our institution
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doi:10.1016/j.jvs.2005.03.015from January 1966 to June 2004 for atherosclerotic single-
vessel BCdisease involving either the SCAor theCCA.Of this
group, 229 patients (group A) underwent operative bypass,
and 162 patients (group B) had percutaneous transluminal
angioplasty (PTA) and stenting. Patients with BC lesions
caused by either inflammatory arteritides or radiation expo-
sure were excluded. When necessary, supplemental informa-
tion was obtained from the patient’s family and private physi-
cian. Demographic and clinical characteristics of the patients
are summarized in Table I.
All patients presented with symptomatic disease that
affected their lifestyle. Our criteria for intervention were
concomitant symptom(s) and angiographic evidence of a
specific culprit lesion. Although the precise presenting
symptoms were successfully documented by chart review,
patient and family interview, and referring physician inter-
view in 375 patients (95.9%), specific presenting symptoms
could not be obtained for 16 (4.1%) very early cases because
of poor chart documentation and patients’ inability to recall
distant events. The specific presenting symptoms in these
16 cases were therefore classified as indeterminate (Table
II). However, among these patients, objective documenta-
tion of an upper extremity blood pressure difference was
noted in eight cases, and each patient had angiographic
documentation of a BC lesion.
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(61.1%) of the 391 patients, upper extremity vascular insuf-
ficiency or emboli were found in 144 patients (36.8%), and
coronary insufficiency (angina) was found in 32 patients
(8.2%) (Table II). Of the patients with cerebrovascular
insufficiency, 225 (57.5%) had symptoms of vertebrobasilar
insufficiency (dizziness, vertigo, imbalance, or drop at-
tacks) related to compromise of posterior cortical flow by a
documented SCA lesion; 14 patients (3.6%) had neurologic
symptoms (transient ischemic attacks or stroke) that corre-
sponded to insufficiency or emboli produced by a docu-
mented CCA lesion. Only 1 of these 14 patients presented
after a (nonhemorrhagic) stroke.
In patients with a stable cardiac status, hemodynamic
changes and symptoms of ischemia in the upper extremities
were reproduced with the method described by Grosveld
Table I. Demographic, clinical, and operative characterist
Characteristic
Group A
(n  229)
Male, n (%) 101 (44.1)
Female, n (%) 128 (55.9)
Age (y)
Mean 59.8
Range 37-84
Risk factors, n (%)
Hypertension 126 (55.0)
Diabetes 26 (11.4)
Known PVOD 59 (25.8)
Tobacco use 123 (53.7)
Previous MI 27 (11.8)
Known CAD 91 (39.7)
Hyperlipidemia 15 (6.6)
COPD 29 (12.7)
NS, Not significant; PVOD, peripheral vascular occlusive disease; MI, my
pulmonary disease.
Table II. Symptoms of brachiocephalic lesions at initial pr
Symptoms
Group A
(n  229)
Cerebrovascular (vascular territory), n (%)‡
Carotid cortical 5 (2.2)
Vertebrobasilar 144 (62.9)
Total 149 (65.1)
Upper extremity, n (%)
Claudication 64 (27.9)
Microembolization 3 (1.3)
Total 67 (29.3)
Angina (CSS related), n (%) 4 (1.7)
Indeterminate, n (%) 16 (7.0)
CCA, Common carotid artery; SCA, subclavian artery; CSS, coronary-subc
*Multiple presenting symptoms were reported in 5 patients (2.2%) in group
was present.
†Anatomic lesion defined by angiography.
‡Cerebral hemispheric symptoms were classified by using the CHAT systemet al.4 Ultrasonic duplex scanning of the BC and vertebralvessels, as well as hemodynamic measurements and neuro-
logic examination, was performed before and after exercise
to differentiate hemodynamically significant lesions from
nonsignificant ones. Extremity exercise was standardized
(1.5 W/s for 5 minutes) by means of an ergonomic appa-
ratus. An examination was considered to have positive
results if any of the following were detected: (1) new or
recurrent vertebrobasilar, hemispheric, or coronary (related
to coronary-subclavian steal syndrome [CSS]) symptoms or
signs; (2) a decrease of 0.15 or more in the blood pressure
index of the ipsilateral arm compared with the contralateral
arm; (3) reversal of flow in the ipsilateral vertebral or carotid
artery; or (4) CCA vessel evaluation that indicated amarked
serial increase in velocity (130 cm/s), a marked serial
decrease in internal carotid artery/CCA velocity ratio, or
spectral broadening. Although neck exposure is limited,
f patients
roup B
 162)
All patients
(n  391) P value
(43.2) 171 (43.7) NS
(56.8) 220 (56.3) NS
64.9 61.9 NS
2-87 32-87
(37.0) 186 (47.6) .0004
(4.3) 33 (8.4) NS
(33.3) 113 (28.9) NS
(26.5) 166 (42.5) .0001
(7.4) 39 (10.0) NS
(40.7) 157 (40.2) NS
(14.2) 38 (9.7) .02
(6.8) 40 (10.2) NS
ial infarction; CAD, coronary artery disease; COPD, chronic obstructive
tation*
Group B
(n  162)
All patients
(n  391)
Anatomic lesion†
Site n (%)
9 (5.6) 14 (3.6) CCA 14 (3.6)
81 (50.0) 225 (57.5) SCA 225 (57.5)
90 (55.6) 239 (61.1) CCA 14 (3.6)
SCA 225 (57.5)
76 (46.9) 140 (35.8) SCA 140 (35.8)
1 (0.6) 4 (1.0) SCA 4 (1.0)
77 (47.5) 144 (36.8) SCA 144 (36.8)
28 (17.3) 32 (8.2) SCA 32 (8.2)
0 (0) 16 (4.1) CCA 3 (0.8)
SCA 13 (3.3)
steal.
33 patients (8.4%) in group B. In each case, a single SCA anatomic lesionics o
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ogy was incorporated, screening and follow-up examina-
tions relied solely on hemodynamic and clinical evaluation.
Positive examination results led to aortic arch and four-
vessel cerebral angiography in each case.
Cerebral hemisphere symptoms were classified with the
CHAT system described by Baker et al5 (Table II). Myo-
cardial perfusion was assessed, and the presence of ischemia
was documented by exercise electrocardiography, thallium
stress testing, or dipyridamole infusion imaging in patients
with stable angina or increased cardiac risk. All patients
underwent a full invasive radiologic evaluation, including
arch aortography with runoff views of the carotid, subcla-
vian, and vertebral circulations and cineangiography of the
coronary vessels when indicated. Vessel stenosis was deter-
mined angiographically with the following formula:
1 diameter at point of greatest stenosis ⁄
diameter at point of greatest patency 100%
In the BC vascular distribution, significant stenosis was
defined as narrowing of the vessel lumen by 80% or more.
Angiography found single-vessel BC disease involving
the CCA in 17 patients (4.3%) and SCA disease in 374
patients (95.7%). In group A (n 229), 15 patients (6.6%)
had CCA disease, and 214 patients (93.4%) had SCA
disease. In group B (n  162), 2 patients (1.2%) had CCA
disease, and 160 patients (98.8%) had SCA disease.
Before endovascular techniques were developed for the
treatment of BC disease, operative bypass was the sole treat-
ment for BC disease at this institution. Although carotid-
subclavian bypass provided excellent long-term durability
when used to treat isolated CCA or SCA disease, we found
that bypass via a cervical approach (rather than a transtho-
racic approach) for innominate artery or multivessel BC
disease produced suboptimal long-term freedom from graft
failure. These results are reported in a companion article.
Endovascular intervention has been used at our institution
for the past 12 years, and for the past 6 years, it has been the
primary treatment for anatomically acceptable lesions in
patients who do not need concomitant multisystem recon-
struction. All patients are entered into our institutional BC
database and followed up closely by defined protocols. The
number of patients with BC disease treated at this institu-
tion increased dramatically over the course of this study.
Reasons for this include an increased awareness of the
problem, increased referrals from outside physicians who
were aware of our interest in the problem, and active
screening of every patient before elective coronary artery
bypass grafting (CABG). To prevent the development of
CSS, each patient being evaluated for elective CABG un-
dergoes angiographic screening of the SCA. If disease is
found in that vessel, then the patient receives arch aortog-
raphy and four-vessel cerebral angiography.
Our operative and endovascular techniques for recon-
structing the great vessels have been reported previously.6-8
Although two reconstruction methods (bypass and PTA)
were used over the course of this study, treatment philoso-
phy, approaches, and techniques were uniform over thistime period because of the influence of one of the authors
(D.A.C.), who has been at our institution since it was
founded. Carotid-subclavian bypass was the sole operative
reconstruction technique used in this study for single-vessel
BC disease. The procedure was performed via an extratho-
racic approach with general anesthesia. Essential features of
this technique include exposure via single incision, a ceph-
alad position of the graft on the SCA, a lateral position of
the graft on the CCA, a short graft length, a graft route
posterior to the jugular vein, and end-to-side anastomoses
using either a Dacron (Hemashield; MeadoxMedicals, Inc,
Oakland,NJ) or a polytetrafluoroethylene conduit. No differ-
ence in outcome was associated with the type of conduit.
A retrograde transbrachial approach was used preferen-
tially in the patients who received PTA as treatment of SCA
disease. In the remaining patients in this study who under-
went PTA, a transfemoral approach was used. This ap-
proach was applied to patients with CCA or SCA disease
that was not amenable to the retrograde transbrachial ap-
proach. Intravascular stents were used routinely, regardless
of the results of angioplasty alone. Distal vessel protection
was used in all patients with CCA lesions. After PTA was
performed, the procedural end point was determined by the
achievement of angiographic success (brisk flow through the
target lesion, no evidence of dissection or thrombosis, and
10% residual stenosis) and hemodynamic success (transste-
notic pressure gradient5 mmHg).
Six patients with chronically occluded vessels were re-
ferred for endovascular intervention. Five were treated
successfully. In one patient, patency could not be estab-
lished in an occluded SCA; this patient subsequently un-
derwent successful operative bypass and was included in
group A. All interventional procedures were performed in
the angiographic suite with local anesthesia and conscious
sedation.
Perioperative myocardial infarction was defined as de-
velopment of new Q waves, elevation of the myocardial
fraction of creatine kinase in association with persistent
ST-segment changes, or development of new conduction
abnormalities. Perioperative stroke was defined as the de-
velopment of a new neurologic focal change on physical
examination and radiologic (computed tomographic) con-
firmation of infarction.
Follow-up clinical and noninvasive examinations were
performed every 6 months in patients who remained symp-
tom free and immediately in patients with recurrent symp-
toms. All patients were discharged on aspirin therapy, and
patients who received endovascular intervention were also
prescribed clopidogrel. Graft or intervention failure was
defined as recurrent stenosis (80%, or 80% with recur-
rent symptoms) determined by angiographic examination
in a single bypass graft or in a native vessel treated with
PTA.
Subjective patient satisfaction was evaluated by using
general and specialty-specific surveys (Press-Ganey Satisfac-
tion Measurement; Press-Ganey Associates, South Bend,
Ind) completed by patients treated for single-vessel BC
disease during the past 4 years (n 180). The surveys were
death.
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Press-Ganey Associates by mail. These standardized surveys
are designed to assess patient satisfaction with care and
outcome and are currently in use at more than 880 medical
centers throughout North America.9-11 The savings benefit
per procedure was computed as the difference between the
mean hospital cost for all operative bypass procedures (n
23) and the mean hospital cost for all endovascular inter-
ventions (n  73) performed between 2002 and 2004.
Hospital cost per patient included all charges other than
surgeons’ fees. For patients who received endovascular
intervention, hospital costs were determined by length of
stay, angiographic suite use, and cost of equipment, includ-
ing catheters and stents. For patients who received opera-
tive bypass, hospital costs were determined by length of
stay, operating room use, and cost of the conduit. The
mean length of stay was 0.6 days for patients who received
endovascular intervention (most of whom did not require
an overnight stay) and 2.6 days for those who received
operative bypass.
Operative results were analyzed for each group by using
the Fisher exact test. Long-term follow-up of the 388
survivors totaled 1711.5 patient-years (mean, 5.2  0.4
years per patient for group A [range, 0.25-30.0 years] and
3.3  0.2 years per patient for group B [range, 0.25-11.6
years]). Patient age, sex, preoperative risk factors, and
presenting symptoms were analyzed by using 2 analysis.
No significant differences were found between groups for
either total CCA-associated or total SCA-associated symp-
toms. Significant differences were found between groups in
the prevalence of hypertension, tobacco use, and hyperlip-
idemia (Table I). Multivariate Cox regression analysis was
used to adjust for these risk factors when the incidence of
long-term events was compared between groups. To fur-
ther evaluate the long-term results, actuarial curves were
obtained by means of Kaplan-Meier statistical analysis with
SAS software (SAS Institute, Cary, NC).
RESULTS
Perioperative adverse events included three operative
deaths, two nonfatal operative strokes, and one myocardial
infarction (Table III). Two operative deaths followed sur-
gical extrathoracic bypass: one was caused by myocardial
infarction 8 days after hospital discharge but within 30 days
of the procedure, and one was caused by stroke. The only
Table III. Operative and late results
Outcome
Mortality, n (%)
Stroke, n (%)
Myocardial infarction, n (%)
Freedom from graft or intervention failure (5 y) (mean  SD)
*One patient had a fatal stroke, which was recorded as both a stroke and a
†P  .03 (Kaplan-Meier); P  .001 (Cox regression analysis).death to follow an endovascular intervention occurred in apatient with preexisting multisystem organ failure in whom
the procedure was performed as a heroic intervention at the
request of the patient’s primary care physician. This patient
had congestive heart failure related to ischemic cardiomy-
opathy. The procedure was performed in an attempt to
reverse the effects of compromised flow in an internal
mammary artery (IMA) coronary conduit caused by prox-
imal SCA disease. Within each group, no significant differ-
ences were found across decades.
Minor complications could not be reliably tabulated in
the operative bypass group. However, in patients who
received endovascular intervention, the minor complica-
tion rate was 5.6% (9/162). Eight of these minor compli-
cations involved the access site (ie, hematoma, need for
surgical repair, and minor wound infections). However, in
one case, brachial artery embolization occurred and neces-
sitated embolectomy.
Freedom from restenosis after operative bypass was
significantly better than that after endovascular interven-
tion in patients with similar preoperative disease (Table III
and Figure). Actuarial freedom from restenosis at 5-year
follow-up was 92.7%  2.1% for operative bypass and
83.9%  3.7% for endovascular intervention (P  .03,
Kaplan-Meier analysis; P  .001, Cox regression analysis).
In the endovascular intervention group, only one of the five
patients treated for a chronically occluded vessel had recur-
rent stenosis during follow-up. Graft or intervention failure
(ie, recurrent stenosis or occlusion) occurred in 14 patients
in group A and 20 patients in group B over the course of the
study.
The clinical patterns of failure differed between groups,
possibly because of differences in the mechanisms of failure in
each group. In group A, graft failure was associated with
thrombosis of the graft in each case, and recurrent symp-
toms were generally similar to those that preceded opera-
tive intervention. These included claudication in three pa-
tients, vertebrobasilar insufficiency in seven patients, and
both in three patients. Only one patient presented with a
new symptom: angina caused by CSS. In group B, inter-
vention failure was associated with either in-stent occlusion
(n  4) or restenosis (n  16), which produced new
symptoms of claudication in 8 patients, recurrent symp-
toms of claudication in 11 patients, and recurrent symp-
toms of vertebrobasilar insufficiency in only 1 patient. Of
the 11 patients, 4 described the recurrent claudication as
Group A
(n  229)
Group B
(n  162)
All patients
(n  391)
2 (0.9)* 1 (0.6) 3 (0.8)
3 (1.3)* 0 (0) 3 (0.8)
1 (0.4) 0 (0) 1 (0.3)
92.7  2.1 83.9  3.7† 89.4  3.0more severe than their preoperative claudication. In group
rcuta
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patients and similar levels of compromise in 11 patients
compared with preintervention anatomy. Definitive con-
clusions are not possible with these small numbers. How-
ever, the patterns of clinical and anatomic failure suggest
that graft failure (thrombosis) may lead to recurrent similar
symptoms as a result of continual blood flow through
native diseased vessels, whereas PTA failure may lead to
new or more severe claudication because of the increased
severity of in-stent restenosis or occlusion compared with
preintervention anatomy.
Recurrent stenosis was treated with repeat operative
intervention in group A and repeat endovascular interven-
tion in group B. In the 14 group A patients with recurrent
disease, all treated arteries remained free from restenosis
after intervention, whereas restenosis occurred again in 5
(25.0%) of the 20 patients in group B. Follow-up data are
summarized in Table IV as freedom from adverse events.
Group A had a 10-year actuarial freedom from graft failure
of 88.1%  3.3%. Because endovascular intervention for BC
disease was introduced relatively recently, 10-year follow-up
data were not available for patients in group B (Table IV).
A relatively large portion of the patients who received
operative bypass required either coronary revascularization
(30.2%  5.1%) or other vascular operation on a system
other than the BC circulation (29.3%  4.6%) in the 10
years after surgery.
Cost analysis based on recent data showed a mean
savings of $8787 per procedure when endovascular inter-
vention, rather than operative bypass, was used to treat
single-vessel BC disease. On the patient satisfaction sur-
veys, 96.5% of patients who received endovascular interven-
tion and 95.1% of patients who received operative bypass as
treatment of single-vessel BC disease rated their treatment
Life-table distribution of actuarial freedom from graft or i
defined as recurrent stenosis greater than 80%, or les
deviations at all time points were less than 10%. PTA, Peas “good” or “very good.”DISCUSSION
As the long-term results of endovascular interventions
come to light, important differences in outcome between
operative bypass and endovascular intervention that will
influence decision making regarding the management of
BC disease will be better understood. Although the free-
dom from graft or intervention failure associated with each
technique is important, other factors—such as the patient’s
operative risk, anatomic distribution of disease, concomi-
tant multisystem disease, initial and late costs, and patient
satisfaction—may affect decision making regarding man-
agement of BC disease in individual patients.
Our results show that mid-term freedom from graft or
intervention failure is significantly better after operative
bypass than after endovascular intervention for the treat-
ment of single-vessel BC disease. It is possible that long-
term follow-up, which is ongoing for both groups of pa-
tients, will reveal an even greater difference in durability
than that found at mid term.
The rates of freedom from restenosis associated with
each type of intervention in this study are consistent with
the results obtained by others in smaller studies. Sullivan
et al12 reported a 35-month actuarial freedom from reste-
nosis of 84% after performing percutaneous angioplasty and
stent placement in 87 vessels of 83 patients with SCA,
CCA, or innominate artery disease. Bates et al13 reported a
5-year actuarial freedom from restenosis of 78% after endo-
vascular intervention in 91 patients with SCA disease.
Uurto et al2 reported actuarial rates of freedom from reste-
nosis of 95% at 5 years and 89% at 10 years in 28 patients after
subclavian-carotid bypass.
Each type of intervention used in this study was associ-
ated with acceptably low perioperative morbidity and mor-
ention failure over time. Graft or intervention failure was
n 80% with associated recurrent symptoms. Standard
neous transluminal angioplasty.nterv
s thatality rates. The complete absence of stroke after endovas-
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two factors: most of the patients in this study had SCA
disease rather than CCA disease, and endovascular inter-
vention has a potential advantage when used to treat SCA
disease. Endovascular treatment of SCA disease does not
involve manipulation of the CCA, whereas operative treat-
ment requires such manipulation for the construction of
a subclavian-carotid bypass. Sullivan et al12 treated more
patients with CCA disease than were treated in this study
and reported 2 (14.3%) ischemic strokes after 14 CCA
endovascular interventions.
Endovascular intervention for BC disease has several
other potential advantages over surgical management. One
of these is shorter hospital stay; endovascular patients are
usually discharged on the day of the procedure, whereas
surgical patients need inpatient care for at least one night.
Endovascular intervention also entails a lower initial cost
(mean savings, $8787 per procedure), is less invasive, and
does not necessitate general anesthesia.
Patterns of failure (ie, recurrent symptom complexes
associated with restenosis) after endovascular intervention
are not completely understood. In certain circumstances
these are of vital importance, in that restenosis may affect
survival. Proximal SCA disease in the presence of an ipsilat-
eral IMA coronary bypass conduit may cause reversal of
IMA flow and produce coronary ischemia (ie, CSS).14,15
Patients with primary and recurrent CSS typically have
angina at presentation.16 However, silent ischemia, isch-
emic cardiomyopathy, and congestive heart failure have
also been reported as modes of presentation.17,18 It is
conceivable that other modes of presentation can occur,
including myocardial infarction and sudden death. In this
setting, close follow-up is essential after SCA reconstruc-
tion whether operative or endovascular intervention is
used. We currently do not use endovascular treatment for
BC disease in conjunction with CABG because the open
surgical treatment of BC disease has proven safe and dura-
ble at our institution, and the need for CABG eliminates
the advantages of PTA that relate to level of invasiveness
and need for anesthesia. However, we do use the endovas-
cular technique in patients who have coronary-subclavian
steal after CABG. These patients are followed up as part of
an ongoing study that maintains strict follow-up with serial
Table IV. Actuarial freedom from specific events at 5- and
n  229) or endovascular intervention (group B; n  162
Event
Group A: 5-y
follow-up (%)
Death 88.6  2.8
Myocardial infarction 89.0  2.8
Stroke 96.9  1.4
Brachiocephalic failure* 93.6  2.1
Coronary revascularization 92.1  2.1
Other vascular operation 85.1  3.0
Data are means  SD.
*Graft or intervention restenosis of either 80% or 80% with symptoms.duplex examinations before and after exercise.4The use of anticoagulation after concomitant BC en-
dovascular intervention as an adjunct to CABG may affect
CABG outcome. We currently use antiplatelet medication
(aspirin and clopidogrel) at the time of stent placement.8 If
a BC stent is placed at the time of cineangiography and
CABG is to be performed as a staged procedure (after endo-
vascular stent placement), the question remains whether to
give antiplatelet medication and risk bleeding during
CABG or to withhold the antiplatelet medication and risk
compromise of stent patency. Additionally, the chest re-
tractor used during CABGmay compress subclavian stents,
deforming them and promoting restenosis.
The lower cost of the endovascular intervention may
represent only a short-term advantage if additional proce-
dures are required for patients with restenosis. Of the 20
patients in this study who were treated for restenosis, 5
(25.0%) have experienced recurrent failure in the same
vessels. It is unclear whether these recurrent stenoses are
related to the patient’s distribution of disease or to an
increased predisposition for restenosis after an initial failure.
Overall, six patients with chronically occluded vessels
were referred for endovascular treatment in this study. This
number, small in comparison to those reported in other
studies,12,13 probably reflects a negative bias on the part of
referring physicians. Most referring physicians in this study
practice medicine, as well as cardiology, and therefore may
have been influenced by reports of the poor freedom from
failure of stents placed in chronically occluded coronary
vessels.19-21 This knowledge probably prompted these phy-
sicians to refer patients with occluded vessels for operative
rather than endovascular intervention. Although few con-
clusions can be drawn from this small group of patients, the
finding of postintervention restenosis in only 1 patient is
similar to the finding by Bates et al13 of postintervention
restenosis in only 1 of 15 patients with baseline occlusions.
We conclude that extrathoracic bypass and endovascu-
lar intervention for single-vessel BC disease are associated
with acceptably low operative morbidity and mortality.
Extrathoracic bypass has significantly better mid-term free-
dom from failure than endovascular intervention and has
excellent long-term durability. Endovascular intervention
offers tangible benefits regarding cost, level of invasiveness,
and subjective patient satisfaction. However, we do not yet
year follow-up after carotid-subclavian bypass (group A;
single-vessel brachiocephalic disease
Group B: 5-y
follow-up (%)
Group A: 10-y
follow-up (%)
96.3  1.2 73.7  4.6
96.3  1.8 84.2  3.6
98.2  1.0 91.4  3.4
83.6  3.7 88.1  3.3
91.4  2.6 69.8  5.1
87.1  3.5 70.7  4.610-
) forknow this technique’s long-term durability, pattern(s) of
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ulation, efficacy as treatment for complex (multivessel)
disease, and long-term cost. Until these additional ques-
tions are answered, the precise indications for endovascular
intervention vs operative reconstruction as treatment of BC
disease remain unsettled. Close follow-up and documenta-
tion of long-term outcomes are necessary in patients receiv-
ing either treatment.
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